Exosomes in Alpha-Synucleinopathies: Propagators of Pathology or Potential Candidates for Nanotherapeutics?

15Citations
Citations of this article
51Readers
Mendeley users who have this article in their library.

Abstract

The pathological accumulation of alpha-synuclein governs the pathogenesis of neurodegenerative disorders, such as Parkinson’s disease, dementia with Lewy bodies, and multiple system atrophy, collectively termed alpha-synucleinopathies. Alpha-synuclein can be released in the extracellular space, partly via exosomes, and this extracellular protein pool may contribute to disease progression by facilitating the spread of pathological alpha-synuclein or activating immune cells. The content of exosomes depends on their origin and includes specific proteins, lipids, functional mRNAs and various non-coding RNAs. Given their ability to mediate intercellular communication via the transport of multilevel information, exosomes are considered to be transporters of toxic agents. Beyond neurons, glial cells also release exosomes, which may contain inflammatory molecules and this glia-to-neuron or neuron-to-glia transmission of exosomal alpha-synuclein may contribute to the propagation of pathology and neuroinflammation throughout the brain. In addition, as their content varies as per their originating and recipient cells, these vesicles can be utilized as a diagnostic biomarker for early disease detection, whereas targeted exosomes may be used as scaffolds to deliver therapeutic agents into the brain. This review summarizes the current knowledge regarding the role of exosomes in the progression of alpha-synuclein-related pathology and their potential use as biomarkers and nanotherapeutics in alpha-synucleinopathies.

References Powered by Scopus

Staging of brain pathology related to sporadic Parkinson's disease

8409Citations
N/AReaders
Get full text

Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes

3859Citations
N/AReaders
Get full text

Extracellular vesicles: Biology and emerging therapeutic opportunities

2754Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Immunological dimensions of neuroinflammation and microglial activation: exploring innovative immunomodulatory approaches to mitigate neuroinflammatory progression

28Citations
N/AReaders
Get full text

Advances in Purification, Modification, and Application of Extracellular Vesicles for Novel Clinical Treatments

17Citations
N/AReaders
Get full text

Environmental pollutants and exosomes: A new paradigm in environmental health and disease

10Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Mavroeidi, P., Vetsi, M., Dionysopoulou, D., & Xilouri, M. (2022, July 1). Exosomes in Alpha-Synucleinopathies: Propagators of Pathology or Potential Candidates for Nanotherapeutics? Biomolecules. MDPI. https://doi.org/10.3390/biom12070957

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 17

77%

Professor / Associate Prof. 4

18%

Researcher 1

5%

Readers' Discipline

Tooltip

Neuroscience 9

53%

Chemistry 3

18%

Medicine and Dentistry 3

18%

Pharmacology, Toxicology and Pharmaceut... 2

12%

Article Metrics

Tooltip
Mentions
Blog Mentions: 1
News Mentions: 1

Save time finding and organizing research with Mendeley

Sign up for free